

**IN THE CLAIMS:**

Please amend claims 1-19 as follows:

1. (Currently Amended) A method of administering chemotherapy, comprising:  
administering use of a first agent that attenuates Topoisomerase I (Topo I) activity; and  
administering a second agent that inhibits Heat Shock Protein 90 (HSP90) activity, ~~in the manufacture of a medicament for~~  
wherein the first agent and the second agent are administered either  
contemporaneously or sequentially ~~contemporaneous or sequential administration in~~  
~~chemotherapy.~~
2. (Currently Amended) The method of use according to claim 1 wherein the first agent is a compound selected from the group consisting of:
  - (i) compounds that bind to Topo I and inhibit its activity;
  - (ii) compounds which prevent the transcription, translation or expression of Topo I;
  - (iii) compounds which inhibit release of Topo I from intracellular stores; and
  - (iv) compounds which increase the rate of degradation of Topo I.
3. (Currently Amended) The method of use according to claim 1 ~~or 2~~ wherein the first agent is a cleavable-complex inhibitor.
4. (Currently Amended) The method of use according to claim 1 ~~or 2~~ wherein the first agent is Camptothecin.
5. (Currently Amended) The method of use according to claim 1 ~~or 2~~ wherein the first agent is Topotecan.

6. (Currently Amended) The method of use ~~according to claim 1 or 2~~ wherein the first agent is Irinotecan.
7. (Currently Amended) The method of use ~~according to claim 1 or 2~~ wherein the first agent is Camptostar (CPT-11).
8. (Currently Amended) The method of use ~~according to claim 1 or 2~~ wherein the first agent is Gemcitabine.
9. (Currently Amended) The method of claim 1 ~~use according to any preceding claim~~ wherein the second agent is a compound selected from the group consisting of:
  - (i) compounds that bind to HSP 90 and inhibit its activity;<sub>2</sub>
  - (ii) compounds which prevent the transcription, translation or expression of HSP 90;<sub>2</sub>
  - (iii) compounds which inhibit release of HSP 90 from intracellular stores;<sub>2</sub> and
  - (iv) compounds which increase the rate of degradation of HSP 90.
10. (Currently Amended) The method of use ~~according to claim 9~~ wherein the second agent is Geldanamycin.
11. (Currently Amended) The method of use ~~according to claim 10~~ wherein the second agent is 17-Allylamino,17-demethoxygeldanamycin (17AAG) or CNF-101.
12. (Currently Amended) The method of use ~~according to claim 9~~ wherein the second agent is Radicicol.
13. (Currently Amended) The method of use ~~according to any preceding claim 1~~ wherein the chemotherapy is for cancer treatment.

14. (Currently Amended) The method of use according to claim 13 for the treatment of solid tumours.
15. (Currently Amended) The method of use according to claim 14 for the treatment of bowel cancer, small cell and non-small cell lung cancer, head and neck cancer, breast cancer, bladder cancer or malignant melanoma.
16. (Currently Amended) The method of use according to claim 15 for the treatment of paediatric tumours.
17. (Currently Amended) The method of use according to claim 13 ~~or 16~~ for the treatment of neuroblastoma, leukaemias and/or ~~and~~ lymphomas.
18. (Currently Amended) The method of claim 1 ~~use according to any one of claims 1—12~~ wherein the chemotherapy is for:
  - antibacterial treatments;<sub>2</sub>
  - antifungal treatments;<sub>2</sub>
  - antiparasitic treatments;<sub>2</sub>
  - the treatment of AIDS/HIV;<sub>2</sub>
  - the treatment of multiple sclerosis;<sub>2</sub> or
  - the killing and inhibition of proliferation of any organism.
19. (Currently Amended) The method of use according to ~~any preceding~~ claim 1 wherein the chemotherapy is for prophylactic treatment.